NCT03966014 Different Amoxicillin Treatment Regimens in Erythema Migrans Patients
| NCT ID | NCT03966014 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University Medical Centre Ljubljana |
| Condition | Erythema Migrans |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2019-06-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 200 participants in total. It began in 2019-06-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to compare the efficacy of different amoxicilline treatment regimens in patients with erythema migrans.
Eligibility Criteria
Inclusion Criteria: * erythema migrans Exclusion Criteria: * pregnancy * extracutaneous manifestations of Lyme borreliosis * immunocompromising state * serious adverse event to beta lactam antibiotic * receiving antibiotic with antiborrelial activity within 10 days
Contact & Investigator
Daša Stupica, MD PhD
PRINCIPAL INVESTIGATOR
Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia
Frequently Asked Questions
Who can join the NCT03966014 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Erythema Migrans. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03966014 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 200 participants.
Is NCT03966014 currently recruiting?
Yes, NCT03966014 is actively recruiting participants. Contact the research team at dasa.stupica@kclj.si for enrollment information.
Where is the NCT03966014 trial being conducted?
This trial is being conducted at Ljubljana, Slovenia, Ljubljana, Slovenia.
Who is sponsoring the NCT03966014 clinical trial?
NCT03966014 is sponsored by University Medical Centre Ljubljana. The principal investigator is Daša Stupica, MD PhD at Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia. The trial plans to enroll 200 participants.